Comparisons

Ozempic vs. Mounjaro: Which GLP-1 Medication Is Better for Weight Loss?

GLP-1 Companion · 8 min read

Ozempic (semaglutide) and Mounjaro (tirzepatide) are the two dominant medications in the GLP-1 class, and patients frequently ask which one is "better." Both are highly effective for blood sugar control and weight loss, but they differ in their mechanisms, clinical trial results, side-effect profiles, and cost. This article provides an evidence-based comparison to help you have an informed conversation with your healthcare provider.

Mechanism of Action: Single vs. Dual Agonist

The most fundamental difference between these two medications is how they work at the receptor level.

• Ozempic (semaglutide): A GLP-1 receptor agonist only. It mimics the incretin hormone GLP-1, stimulating insulin release, suppressing glucagon, slowing gastric emptying, and reducing appetite.
• Mounjaro (tirzepatide): A dual GLP-1 and GIP receptor agonist. It activates both the GLP-1 and GIP pathways simultaneously, which may produce additive or synergistic metabolic benefits beyond what GLP-1 activation alone can achieve.

Head-to-Head Clinical Data: SURPASS-2

The SURPASS-2 trial is the most important direct comparison. This randomized, open-label trial enrolled 1,879 adults with type 2 diabetes and compared tirzepatide (5 mg, 10 mg, and 15 mg) to semaglutide 1 mg over 40 weeks.

HbA1c Reduction

• Semaglutide 1 mg: −1.86%
• Tirzepatide 5 mg: −2.01% (superior to semaglutide)
• Tirzepatide 10 mg: −2.24% (superior to semaglutide)
• Tirzepatide 15 mg: −2.30% (superior to semaglutide)

Weight Loss

• Semaglutide 1 mg: −6.2 kg (13.7 lbs)
• Tirzepatide 5 mg: −7.6 kg (16.8 lbs)
• Tirzepatide 10 mg: −9.3 kg (20.5 lbs)
• Tirzepatide 15 mg: −12.4 kg (27.3 lbs)

All three tirzepatide doses were statistically superior to semaglutide 1 mg for both HbA1c reduction and weight loss. It is worth noting, however, that the trial compared tirzepatide's full dose range against only the 1 mg dose of semaglutide—not the 2 mg dose that is now available, nor the 2.4 mg weight-loss dose used in Wegovy.

No head-to-head trial has yet compared tirzepatide at its highest dose (15 mg) against semaglutide at its highest dose (2.4 mg). Until such a trial is conducted, cross-trial comparisons should be interpreted cautiously.

Weight Loss: Cross-Trial Comparison

While direct head-to-head data at maximum doses is lacking, comparing results across their respective obesity trials gives a useful (though imperfect) picture:

• Wegovy (semaglutide 2.4 mg) in STEP 1: −14.9% body weight over 68 weeks in adults without diabetes.
• Zepbound (tirzepatide 15 mg) in SURMOUNT-1: −22.5% body weight over 72 weeks in adults without diabetes.
• The difference—roughly 7.5 percentage points—is substantial, though the trials had different designs, populations, and durations.

Side Effects Comparison

Both medications share a similar gastrointestinal side-effect profile, as expected for incretin-based therapies. The rates are broadly comparable, with some nuances.

• Nausea: Reported in approximately 20–24% of patients on both medications during dose escalation. Tends to improve over time.
• Diarrhea: Slightly more common with tirzepatide in some trials (12–17% vs 8–12% with semaglutide).
• Vomiting: Similar rates (5–10%) for both.
• Constipation: Reported with both; may be slightly more common with semaglutide.
• Injection site reactions: Similar for both; generally mild.
• Discontinuation due to side effects: 4–7% for tirzepatide vs 3–5% for semaglutide across trials.

Both medications carry boxed warnings for thyroid C-cell tumors based on animal data and warnings for pancreatitis, gallbladder disease, and hypoglycemia (particularly when used with insulin or sulfonylureas).

Cost and Insurance

Cost is a practical consideration that often drives the final decision between these medications.

• Ozempic list price: Approximately $935–$1,350 per month without insurance.
• Mounjaro list price: Approximately $1,175 per month without insurance.
• Both manufacturers offer savings cards for eligible commercially insured patients, potentially reducing copays to $25–$150 per month.
• Insurance formulary placement varies: some plans prefer semaglutide, others prefer tirzepatide. Prior authorization is common for both.
• Neither is a generic medication, so costs remain high for cash-pay patients.

Cardiovascular Benefits

Semaglutide has a proven cardiovascular advantage: the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease. Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) is ongoing, with results expected in the coming years. Until that data is available, semaglutide holds an edge for patients whose primary concern is cardiovascular risk reduction.

Which Is Right for You?

There is no single "better" medication—the right choice depends on your individual health profile, goals, and practical circumstances.

• Choose Mounjaro/tirzepatide if: Maximum weight loss is your priority, you tolerate GI side effects reasonably well, and your insurance covers it.
• Choose Ozempic/semaglutide if: You have established cardiovascular disease and want proven CV risk reduction, your insurance favors semaglutide, or you prefer a medication with a longer track record.
• Consider starting with semaglutide if: You want to try the class with a well-studied safety profile and switch to tirzepatide later if results are insufficient.
• Discuss with your provider: Individual responses vary. Some patients respond better to one medication than the other, and the only way to know is through careful monitoring.

The Bottom Line

Ozempic (semaglutide) and Mounjaro (tirzepatide) are both highly effective GLP-1-based medications. Tirzepatide's dual mechanism has produced superior weight loss and HbA1c reduction in head-to-head and cross-trial comparisons, but semaglutide has stronger cardiovascular outcome data and a longer history of clinical use. Cost, insurance coverage, side-effect tolerance, and cardiovascular risk should all factor into your decision. The most important step is having an open, informed conversation with your healthcare provider about which medication aligns best with your health goals.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.